Drug intelligence / Profile preview

Lankof

Development stage
Unknown
Lead developer
Lancet
Modality
Small Molecules
Administration
Oral
01

Overview

Lankof is a combination pharmaceutical product developed and marketed by Lancet Pharmaceuticals, an Indian branded generic company. It is primarily indicated for the relief of productive cough associated with respiratory conditions such as bronchitis, bronchial asthma, and other bronchospastic disorders. The formulation typically contains four active ingredients: terbutaline, ambroxol, guaifenesin, and menthol. Terbutaline acts as a selective beta-2 adrenergic agonist, providing bronchodilation by relaxing the smooth muscles of the airways. Ambroxol serves as a mucolytic agent that thins and loosens mucus, facilitating its clearance from the respiratory tract. Guaifenesin is an expectorant that increases the volume and reduces the viscosity of secretions in the trachea and bronchi. Menthol is included for its soothing properties and its ability to provide a cooling sensation in the throat, which helps alleviate irritation.

Brand names
LankofLankof Syrup
02

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)ADRB2 (β2)

Beyond the preview

Go deeper on Lankof.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lankof.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call